Precigen, Inc. (NASDAQ: PGEN) is a Healthcare company (Biotechnology) with a market capitalization of $1.5B. The Maz Rating grades it against the other companies in its sector.
Precigen, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.29, Precigen, Inc. trades at 63.0x trailing earnings, 9.8x sales and 18.4x book value, with an EV/EBITDA of 39.8. Over the last twelve months it generated about $157M of revenue and $24M of net income. It runs a gross margin of 91.0%, an operating margin of 21.4% and a net margin of 15.6%. It shows return on equity of 57.9%, return on invested capital of 18.3% and a free cash flow yield of -4.9%. On the balance sheet: a debt-to-equity ratio of 1.18 and a current ratio of 5.58. Over the past 52 weeks the share price ranged from $3.04 to $8.98, with a beta of 0.98.
Precigen, Inc. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 11 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Precigen, Inc. (PGEN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.92% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.12% / 30% · Interest income / Revenue 0.44% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 3.92% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 1.91% / 33% · Receivables / Mkt Cap (36m) 4.02% / 49% · Interest income / Revenue 0.44% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 3.92% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 1.91% / 33.33% · Receivables / Mkt Cap (24m) 4.02% / 33.33% · Interest income / Revenue 0.44% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 55.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 35.2% / 33.33% · Receivables / Avg Assets (4Q) 29.5% / 33.33% · Interest income / Revenue 0.44% / 5% | Fail |
| FTSE | Debt / Total Assets 44.4% / 33.33% · (Cash+ST Inv) / Total Assets 21.7% / 33.33% · (Cash+Recv) / Total Assets 67.3% / 33.33% · Interest income / Revenue 0.44% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Precigen, Inc. (PGEN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Precigen, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.44% of each dividend: Precigen, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.